Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

S
Sánchez, Belén

Vall d'Hebron Institute of Oncology (VHIO)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Belén Sánchez
Favorite
Sönnert-Husa, Sonja

Center for clinical cancer studies, Karolinska University Hospital
2001 - Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
Sonja Sönnert-Husa
Favorite
Saeed, Hayder

H Lee Moffitt Cancer Center & Research Institute
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Hayder Saeed
Favorite
Saggau, Julia

Department I for Internal Medicine, University Hospital Cologne
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Julia Saggau
Favorite
Saha, Aditi

Moffitt Cancer Center
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Aditi Saha
Favorite
Sahakian, Eva

H Lee Moffitt Cancer Center & Research Institute
1026 - Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia
Eva Sahakian
Favorite
1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Eva Sahakian
Favorite
1058 - T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors
Eva Sahakian
Favorite
Sajkowski, Shawn
1213 - An examination of health literacy amongst patients with Chronic Lymphocytic Leukemia- A study from The Lymphoma Coalition Global Patient Survey 2022.
Shawn Sajkowski
Favorite
Sakellari, Ioanna
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Ioanna Sakellari
Favorite
Salerno, Domenico
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Domenico Salerno
Favorite
Salido, Marta

Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain/Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
1152 - Optical genome mapping and fluorescence in situ hybridization is the best combination to identify genomic complexity and TP53 deletions in CLL patients
Marta Salido
Favorite
Salmi, Tommi

BeiGene (Beijing) Co, Ltd., Beijing, China and BeiGene USA, Inc, San Mateo, CA, USA
2013 - Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Tommi Salmi
Favorite
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Tommi Salmi
Favorite
Salvetti, Chiara

Department of Internal Medicine, Clinic of Hematology, University of Genoa
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Chiara Salvetti
Favorite
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Chiara Salvetti
Favorite
Sampath, Deepa

Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Deepa Sampath
Favorite
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Deepa Sampath
Favorite
Sampietro, Marta
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Marta Sampietro
Favorite
Samples, Laura

Fred Hutchinson Cancer Center
1106 - Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Laura Samples
Favorite
Sancetta, Rosaria

Ospedale dell’Angelo
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Rosaria Sancetta
Favorite
Sanchez Garcia de los Rios, Mateo
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Mateo Sanchez Garcia de los Rios
Favorite
Sandaltzopoulos, Raphael
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Raphael Sandaltzopoulos
Favorite
Sanna, Alessandro

Azienda Ospedaliera Universitaria di Careggi
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Alessandro Sanna
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Alessandro Sanna
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Alessandro Sanna
Favorite
Santos Azevedo, Roberta

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Hospital Nove de Julho, São Paulo, SP, BR
1040 - Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia
Roberta Santos Azevedo
Favorite
Santos Mínguez, Sandra

University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca, Salamanca
1161 - ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
Sandra Santos Mínguez
Favorite
Sarapura Martinez, Valeria

Instituto de Medicina Experimental - CONICET - Academia Nacional de Medicina
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Valeria Sarapura Martinez
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Valeria Sarapura Martinez
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Valeria Sarapura Martinez
Favorite
Sarkozy, Clémentine

Institut Curie, Saint-Cloud Hospital
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Clémentine Sarkozy
Favorite
Sarmiento, Lindybeth

Universidad de Magallanes
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Lindybeth Sarmiento
Favorite
Savara, Jakub
1157 - Significance of TP53 aberrations in context of other pathogenic sequence variants in patients with chronic lymphocytic leukemia in the era of targeted therapy
Jakub Savara
Favorite
Savvulidi Vargova, Karina

Charles University, First Faculty of Medicine, Institute of Pathological Physiology
1015 - Coupled effect of a miR-155 deficiency and hypoxia conditions leads to the upregulation of SLC2A1 (GLUT1), SLC2A3 (GLUT3) and EGLN1 genes in the leukemic B-cells
Karina Savvulidi Vargova
Favorite
Scarano, Eloise

IRCCS Ospedale San Raffaele
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Eloise Scarano
Favorite
Scarfò, Lydia

Vita-Salute San Raffaele University
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Lydia Scarfò
Favorite
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Lydia Scarfò
Favorite
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Lydia Scarfò
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Lydia Scarfò
Favorite
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Lydia Scarfò
Favorite
Schachter, Levanto

Oregon Health & Science Universit
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Levanto Schachter
Favorite
Schiattone, Luana

Presidio Ospedaliero S.Spirito di Pescara
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Luana Schiattone
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Luana Schiattone
Favorite
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Luana Schiattone
Favorite
Schlag, Rudolf

Practice for Hematology and Oncology Würzburg & Kitzingen
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Rudolf Schlag
Favorite
Schmidt, Burkhard

Center for Translational Cancer Research (TranslaTUM), Technical University Munich, Klinikum rechts der Isar
1105 - SAFETY AND EFFECTIVENESS IN CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY IN AUSTRIA, GERMANY, AND SWITZERLAND - LONG TERM FOLLOW UP DATA
Burkhard Schmidt
Favorite
Schmitt, Clemens A.

Department of Hematology and Internal Oncology, Kepler University Hospital, Johannes Kepler University
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Clemens A. Schmitt
Favorite
Schreurs, Luca

Department I for Internal Medicine, University Hospital Cologne
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Luca Schreurs
Favorite
Schroeter, Nicole

CLL Advocates Network
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Nicole Schroeter
Favorite
Schuh, Anna

Oxford Molecular Diagnostic Centre, Department of Oncology, University of Oxford
1202 - T cell type abundance and gene expression patterns in the context of clinical progression of treatment-naïve CLL/MBL patients from the OxPLoreD study
Anna Schuh
Favorite
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Anna Schuh
Favorite
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Anna Schuh
Favorite
Schuster, Stephen J.

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Stephen J. Schuster
Favorite
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Stephen J. Schuster
Favorite
Schwager, Susan

Mayo Clinic
1121 - Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents
Susan Schwager
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Susan Schwager
Favorite
Schwaner, Ingo

Onkologische Schwerpunktpraxis Kurfürstendamm
1105 - SAFETY AND EFFECTIVENESS IN CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY IN AUSTRIA, GERMANY, AND SWITZERLAND - LONG TERM FOLLOW UP DATA
Ingo Schwaner
Favorite
Schwarer, Anthony
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Anthony Schwarer
Favorite
Scielzo, Cristina

IRCCS, Hospital San Raffaele
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Cristina Scielzo
Favorite
Scortechini, Ilaria

Azienda ospedaliero Universitaria delle Marche
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Ilaria Scortechini
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Ilaria Scortechini
Favorite
Scott, Hamish

Peter MacCallum Cancer Center
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Hamish Scott
Favorite
Searle, Emma

Manchester Cancer Research Centre, Division of Cancer Sciences
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Emma Searle
Favorite
Seda, Vaclav

CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Vaclav Seda
Favorite
Seiffert, Martina

German Cancer Research Center
1057 - Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Martina Seiffert
Favorite
Seo, Dave

MD Anderson Cancer Center
1137 - Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)
Dave Seo
Favorite
Sepulveda-Yañez, Julieta

Universidad de Magallanes
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Julieta Sepulveda-Yañez
Favorite
Seshan, Venkatraman

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Venkatraman Seshan
Favorite
Severin, Filippo

University of Padua
1016 - DEFACTINIB AFFECTS CHRONIC LYMPHOCYTIC LEUKEMIA CELL SURVIVAL WITH ADDITIVE EFFECT IN COMBINATION WITH BTK INHIBITORS
Filippo Severin
Favorite
Seymour, John

Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
John Seymour
Favorite
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
John Seymour
Favorite
Shadman, Mazyar

Fred Hutchinson Cancer Center / University of Washington School of Medicine
1106 - Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Mazyar Shadman
Favorite
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Mazyar Shadman
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Mazyar Shadman
Favorite
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Mazyar Shadman
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Mazyar Shadman
Favorite
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Mazyar Shadman
Favorite
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Mazyar Shadman
Favorite
Shah, Bijal

H Lee Moffitt Cancer Center & Research Institute
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Bijal Shah
Favorite
Shah, Nirav

Medical College of Wisconsin
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Nirav Shah
Favorite
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Nirav Shah
Favorite
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Nirav Shah
Favorite
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Nirav Shah
Favorite
Shah, Pratik

Northwell Health
1226 - Outcomes of Tixagevimab/cilgavimab pre-exposure prophylaxis in Chronic lymphocytic leukemia patients- a single center experience
Pratik Shah
Favorite
Shaikh, Nazneen Fatima

IQVIA
2007 - Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Nazneen Fatima Shaikh
Favorite
Shang, Chunyu
1017 - NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia
Chunyu Shang
Favorite
Sharma, Esha

The Feinstein Institutes for Medical Research, Northwell Health
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Esha Sharma
Favorite
Sharman, Jeff

Willamette Valley Cancer Institute
1110 - Systematic literature review (SLR) of treatments and outcomes in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitors (BTKi) and venetoclax
Jeff Sharman
Favorite
1204 - Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry
Jeff Sharman
Favorite
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Jeff Sharman
Favorite
Sha, Yeqin

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Yeqin Sha
Favorite
1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Yeqin Sha
Favorite
1128 - Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Yeqin Sha
Favorite
1145 - The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Yeqin Sha
Favorite
1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Yeqin Sha
Favorite
1228 - Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Yeqin Sha
Favorite
Shen, Hui

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Hui Shen
Favorite
Shen, Yandong

Royal North Shore Hospital
1132 - Very low COVID mortality and hospitalization rates in CLL and MBL with repeated vaccination to maximum antibody response
Yandong Shen
Favorite
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Yandong Shen
Favorite
Sherburne, Maryanne

Massachusetts General Hospital Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Maryanne Sherburne
Favorite
Shetty, Vikram

AstraZeneca
1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
Vikram Shetty
Favorite
Shi, Ling

Evidera PPD
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Ling Shi
Favorite
Shi, Min

Mayo Clinic
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Min Shi
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Min Shi
Favorite
1229 - A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
Min Shi
Favorite
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Min Shi
Favorite
Shimoni, Shai
1113 - Pericardial effusion in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors
Shai Shimoni
Favorite
Shi, Yu
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Yu Shi
Favorite
Shouse, Geoffrey

City of Hope National Medical Center
1210 - A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Geoffrey Shouse
Favorite
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Geoffrey Shouse
Favorite
Shukla, Sachet Ashok

University of Texas MD Anderson Cancer Center
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Sachet Ashok Shukla
Favorite
Shupe, Samantha

Dana-Farber Cancer Institute
1040 - Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia
Samantha Shupe
Favorite
1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Samantha Shupe
Favorite
Shu, Shi

Lymphoid Malignancies Section, Hematology Branch, NHLBI, NIH
1041 - Anti-FcμR Antibody Drug Conjugate as a Potential Therapeutic Agent for the Treatment of Chronic Lymphocytic Leukemia
Shi Shu
Favorite
Siddiqi, Tanya

City of Hope National Medical Center
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Tanya Siddiqi
Favorite
1210 - A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Tanya Siddiqi
Favorite
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Tanya Siddiqi
Favorite
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Tanya Siddiqi
Favorite
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Tanya Siddiqi
Favorite
Sierra, Jordi

Hospital de la Santa Creu i Sant Pau
1104 - Non-Hematological Autoimmune Disorders are frequent in CLL, but are they clinically related? Data from a Single-center Real-Life Cohort
Jordi Sierra
Favorite
1117 - EVOLUTION IN THE FRONTLINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EXPERIENCE FROM ONE EUROPEAN CENTER
Jordi Sierra
Favorite
1118 - Similar discriminatory values of IPS-E, AIPSE, and CR0 scores predicting time to first treatment in a large series of unselected patients with early-stage CLL
Jordi Sierra
Favorite
1129 - Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Jordi Sierra
Favorite
Simon-Molas, Helga

Amsterdam University Medical Centers
1024 - Impaired mitochondrial metabolism drives T-cell dysfunction in chronic lymphocytic leukemia
Helga Simon-Molas
Favorite
Sincic-Petricevic, Jasminka

University Hospital Centre Osijek
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Jasminka Sincic-Petricevic
Favorite
Sinet, Pierre

Janssen
2028 - Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Pierre Sinet
Favorite
Sinha, Sutapa

Mayo Clinic, Rochester
2006 - Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression
Sutapa Sinha
Favorite
Sivcheva, Lilly

First Internal Department, MHAT Hristo Botev, AD
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Lilly Sivcheva
Favorite
Skånland, Sigrid

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Sigrid Skånland
Favorite
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Sigrid Skånland
Favorite
Skarbnik, Alan

Novant Health Cancer Institute
1143 - The Economic Benefits of Time Off Treatment: Real-World HRU, Costs, and Subsequent Treatment with Fixed Duration Venetoclax among Patients with Chronic Lymphocytic Leukemia
Alan Skarbnik
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Alan Skarbnik
Favorite
1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
Alan Skarbnik
Favorite
Slager, Susan

Mayo Clinic
1121 - Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents
Susan Slager
Favorite
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Susan Slager
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Susan Slager
Favorite
1229 - A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
Susan Slager
Favorite
2006 - Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression
Susan Slager
Favorite
Slavutsky, Irma

Academia Nacional de Medicina
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Irma Slavutsky
Favorite
Slawin, Bailey
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Bailey Slawin
Favorite
Slupe, Natalie

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Natalie Slupe
Favorite
Smagghe, Luce
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Luce Smagghe
Favorite
Smida, Michal

Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno
1001 - Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genome-wide CRISPR screening
Michal Smida
Favorite
Smith, Stephen

Fred Hutchinson Cancer Center / University of Washington School of Medicine
1106 - Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Stephen Smith
Favorite
Smolej, Lukáš

4th Department of Internal Medicine – Hematology, University Hospital and Charles University Faculty of Medicine in Hradec Králové
1136 - Serum Monoclonal Immunoglobulin Predicts Inferior Prognosis in Patients Treated for Chronic Lymphocytic Leukemia
Lukáš Smolej
Favorite
1156 - Real-world Effectiveness and Safety of Tixagevimab/Cilgavimab Lower Dosage Regimen in Pre-Exposure Prophylaxis in Patients Undergoing Treatment for Chronic Lymphocytic Leukemia
Lukáš Smolej
Favorite
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Lukáš Smolej
Favorite
1215 - Unveiling the Spectrum of Genetic Alterations in Relapsed/Refractory CLL Patients on Targeted Inhibitors: A Prospective Unicentric Study
Lukáš Smolej
Favorite
1217 - Evolution of natural history and prolongation of overall survival in patients with chronic lymphocytic leukemia: analysis of a long-term follow-up of an unselected cohort in the Hradec Králové district, Czech Republic.
Lukáš Smolej
Favorite
Sofou, Electra
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Electra Sofou
Favorite
Sokol, Lobomir

H Lee Moffitt Cancer Center & Research Institute
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Lobomir Sokol
Favorite
Solomon, Scott R.

Northside Hospital Cancer Institute
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Scott R. Solomon
Favorite
Somanath, Priyanka

Biomea Fusion, Inc.
2019 - Covalent menin inhibitor, BMF-219, impacts key gene signatures and molecular pathways in Chronic Lymphocytic Leukemia patient-derived models
Priyanka Somanath
Favorite
Song, Xingyu
1149 - Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel
Xingyu Song
Favorite
Soric, Ena

University Hospital Dubrava
1019 - Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy
Ena Soric
Favorite
1130 - Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment
Ena Soric
Favorite
Soumerai, Jacob

Center for Lymphoma, Massachusetts General Hospital Cancer Center
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Jacob Soumerai
Favorite
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Jacob Soumerai
Favorite
Souto, Jorge

Institut Pasteur de Montevideo
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Jorge Souto
Favorite
Spaanderman, Ide

1 Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam institute for Infection and Immunity, Amsterdam, The Netherlands; 3 Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
1044 - T cells from chronic lymphocytic leukemia patients are not exhausted but show signs of senescence, providing alternative clues for improvement
Ide Spaanderman
Favorite
Spassov, Emil

Clinic of Hematology, UMHAT St George and Medical University
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Emil Spassov
Favorite
Spina, Valeria

Institute of Oncology Research
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Valeria Spina
Favorite
Sportoletti, Paolo

A.O. Santa Maria della Misericordia di Perugia
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Paolo Sportoletti
Favorite
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Paolo Sportoletti
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Paolo Sportoletti
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Paolo Sportoletti
Favorite
Spurgeon, Stephen

Oregon Health and Science University
1210 - A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Stephen Spurgeon
Favorite
Srinivasan, Srimathi

Janssen
2028 - Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Srimathi Srinivasan
Favorite
Stachelscheid, Johanna

Cologne Excellence Cluster on Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Johanna Stachelscheid
Favorite
Stamatopoulos, Basile

Jules Bordet Institute - Laboratory of Clinical Cell Therapy
1036 - Chronic lymphocytic leukemia extracellular vesicles induce the differentiation of monocytes into nurse-like cells
Basile Stamatopoulos
Favorite
Stamatopoulos, Kostas

CERTH
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Kostas Stamatopoulos
Favorite
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Kostas Stamatopoulos
Favorite
Stanganelli, Carmen

Academia Nacional de Medicina
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Carmen Stanganelli
Favorite
Stavroyianni, Niki
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Niki Stavroyianni
Favorite
Steffan, Agostino
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Agostino Steffan
Favorite
Steiner, Normann

Department of Internal Medicine V, Medical University Innsbruck
1141 - Reduced predictive value of elevated Beta-2-microglobulin plasma levels on time to first treatment in newly diagnosed CLL patients with compromised kidney function
Normann Steiner
Favorite
Stephens, Deborah M.

Lineberger Cancer Center, University of North Carolina
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Deborah M. Stephens
Favorite
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Deborah M. Stephens
Favorite
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Deborah M. Stephens
Favorite
Stevens, Wendy

Radboud UMC, Nijmegen, on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON /LLPC
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Wendy Stevens
Favorite
Stewart, Katherine

AstraZeneca
1220 - Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials (RCTs)
Katherine Stewart
Favorite
Stewart, Sandra

Weill Cornell Medicine
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
Sandra Stewart
Favorite
Stilgenbauer, Stephan

Department of Internal Medicine III, Ulm University
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Stephan Stilgenbauer
Favorite
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Stephan Stilgenbauer
Favorite
Stocker, Nicolas
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Nicolas Stocker
Favorite
Stolzlechner, Valentina

Department of Internal Medicine V, Medical University Innsbruck
1141 - Reduced predictive value of elevated Beta-2-microglobulin plasma levels on time to first treatment in newly diagnosed CLL patients with compromised kidney function
Valentina Stolzlechner
Favorite
Stong, Nicholas

Bristol Myers Squibb
1134 - High deletion burden identified by whole genome sequencing is associated with enhanced risk in del17p CLL patients
Nicholas Stong
Favorite
Stott, Lauren

Brighton and Sussex Medical School
1005 - Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Lauren Stott
Favorite
1023 - Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
Lauren Stott
Favorite
Strumberg, Dirk
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Dirk Strumberg
Favorite
Stuckey, Jeanne

Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Jeanne Stuckey
Favorite
Subbiah, Suki

LSU Health Science Center
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Suki Subbiah
Favorite
Sun, William

Prelude Therapeutics
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
William Sun
Favorite
Sun, Yu
1149 - Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel
Yu Sun
Favorite
Sutton, Lesley Ann
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Lesley Ann Sutton
Favorite
Suzuki, Ritsuro

Shimane University Hospital
1126 - Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease.
Ritsuro Suzuki
Favorite
Suzumiya, Junji

Department of Hematology, Koga Community Hospital
1126 - Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease.
Junji Suzumiya
Favorite
Svensson, Magnus

Department of Medicine, Eskilstuna Hospital
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Magnus Svensson
Favorite
Sylvan, Sandra Eketorp

Department of Oncology-Pathology, Karolinska Institutet
1125 - Frequent monitoring in chronic lymphocytic leukemia clinical trials: what is the true value?
Sandra Eketorp Sylvan
Favorite
Symeonidis, Konstantinos
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Konstantinos Symeonidis
Favorite
Szeto, Andy

BeiGene USA, Inc.
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Andy Szeto
Favorite